Vantia Therapeutics appoints new CEO
This article was originally published in Scrip
Vantia Therapeutics (UK) has named Andrew Crockett chief executive officer. He joined the company in 2009 as vice-president of business development from the US speciality pharma firm ZARS Pharma. Vantia, which was formed in 2008 as a spin-out of Ferring Research's small-molecule R&D, has two clinical phase products – VA106483 for the treatment of nocturia and VA111913 for the treatment of dysmenorrhoea.